What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
JACC. CardioOncology - 4(2022), 5 vom: 20. Dez., Seite 624-628 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thuny, Franck [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 15.01.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jaccao.2022.06.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351473807 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351473807 | ||
| 003 | DE-627 | ||
| 005 | 20231226051441.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaccao.2022.06.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1171.xml |
| 035 | |a (DE-627)NLM351473807 | ||
| 035 | |a (NLM)36636431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thuny, Franck |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor-Induced Myocarditis? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.01.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 2018-LL, 2018-Lake Louise | |
| 650 | 4 | |a ACS, acute coronary syndrome | |
| 650 | 4 | |a CMR, cardiac magnetic resonance | |
| 650 | 4 | |a ECG, electrocardiogram | |
| 650 | 4 | |a EMB, endomyocardial biopsy | |
| 650 | 4 | |a IC-OS, International Cardio-Oncology Society | |
| 650 | 4 | |a ICI, immune checkpoint inhibitor | |
| 650 | 4 | |a ICI-M, immune checkpoint inhibitor–induced myocarditis | |
| 650 | 4 | |a LGE, late gadolinium enhancement | |
| 650 | 4 | |a MACE, major cardiovascular events | |
| 650 | 4 | |a cTn, cardiac troponin | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a irAE, immune-related adverse event | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a screening | |
| 700 | 1 | |a Bonaca, Marc P |e verfasserin |4 aut | |
| 700 | 1 | |a Cautela, Jennifer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JACC. CardioOncology |d 2019 |g 4(2022), 5 vom: 20. Dez., Seite 624-628 |w (DE-627)NLM307928136 |x 2666-0873 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2022 |g number:5 |g day:20 |g month:12 |g pages:624-628 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaccao.2022.06.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2022 |e 5 |b 20 |c 12 |h 624-628 | ||